Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Clinical outcomes of patients with FLT3-ITD-mutated R/R AML undergoing HSCT...

Dr Siddhartha Ganguly - The University of Kansas Health System, Kansas City, USA

Clinical outcomes of patients with FLT3-ITD-mutated R/R AML undergoing HSCT after quizartinib or salvage chemo ( Dr Siddhartha Ganguly - The University of Kansas Health System, Kansas City, USA )

Outcomes in patients with therapy-Related AML who achieved remission with CPX...

Dr Jeffrey Lancet - H. Lee Moffitt Cancer Center & Research Institute, Tampa...

Outcomes in patients with therapy-Related AML who achieved remission with CPX-351 versus 7 plus 3: Phase 3 exploratory analysis ( Dr Jeffrey Lancet - H. Lee Moffitt Cancer Center & Research Institute, Tampa, USA )

Selective oestrogen receptor degraders as treatment for ER positive/HER2...

Dr Philippe Aftimos - Institut Jules Bordet, Brussels, Belgium

Selective oestrogen receptor degraders as treatment for ER positive/HER2 negative advanced/metastatic breast cancer ( Dr Philippe Aftimos - Institut Jules Bordet, Brussels, Belgium )

The challenges of treating breast cancer in Brazil

Dr Felipe Ades - Hospital Alemão Oswaldo Cruz, São Paulo, Brazil

The challenges of treating breast cancer in Brazil ( Dr Felipe Ades - Hospital Alemão Oswaldo Cruz, São Paulo, Brazil )

The importance of central pathology pCR review in an international multicenter...

Dr Hans-Christian Kolberg - Marienhospital, Bottrop, Germany

The importance of central pathology pCR review in an international multicenter neoadjuvant study in HER2 positive early BC ( Dr Hans-Christian Kolberg - Marienhospital, Bottrop, Germany )

SABCS 2019 highlights

Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy

SABCS 2019 highlights ( Dr Matteo Lambertini - San Martino Hospital, Genoa, Italy )

The PEARL study: Palbociclib and endocrine therapy vs capecitabine in HR /HER2...

Dr Miguel Martín - Universidad Complutense de Madrid, Madrid, Spain

The PEARL study: Palbociclib and endocrine therapy vs capecitabine in HR /HER2- metastatic breast cancer ( Dr Miguel Martín - Universidad Complutense de Madrid, Madrid, Spain )

Imaging for women who are high risk of breast cancer

Dr Maxine Jochelson - Memorial Sloan Kettering Cancer Center, New York City, USA

Imaging for women who are high risk of breast cancer ( Dr Maxine Jochelson - Memorial Sloan Kettering Cancer Center, New York City, USA )

Adding S-1 to post-operative endocrine therapy in patients with hormone...

Prof Masakazu Toi - Kyoto University, Kyoto, Japan

Adding S-1 to post-operative endocrine therapy in patients with hormone receptor-positive HER2-negative breast cancer ( Prof Masakazu Toi - Kyoto University, Kyoto, Japan )

Exploring adjuvant endocrine therapy use with letrozole in postmenopausal women...

Dr Terry Mamounas - Orlando Health UF Health Cancer Center, Orlando, USA

Exploring adjuvant endocrine therapy use with letrozole in postmenopausal women with hormone receptor-positive breast cancer ( Dr Terry Mamounas - Orlando Health UF Health Cancer Center, Orlando, USA )

KEYNOTE-522: Neoadjuvant pembro chemo vs placebo chemo, followed by...

Dr Jay Andersen - Compass Oncology West Cancer Center, Tigard, USA

KEYNOTE-522: Neoadjuvant pembro chemo vs placebo chemo, followed by adjuvant pembro vs placebo for early TNBC ( Dr Jay Andersen - Compass Oncology West Cancer Center, Tigard, USA )

Residual cancer burden after neoadjuvant therapy and long-term survival...

Prof William Symmans - MD Anderson Cancer Center, Houston, Texas

Residual cancer burden after neoadjuvant therapy and long-term survival outcomes in breast cancer ( Prof William Symmans - MD Anderson Cancer Center, Houston, Texas )

More from ecancer